Browsing by Author "Lluch, Ana"

Sort by: Order: Results:

  • Broad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of spanish medical oncologists
    Sánchez-Rovira, Pedro; Zamora, Pilar; Salvador-Bofill, Javier; Morales, Serafín; Martínez-Jáñez, Noelia; Martínez-de-Dueñas, Eduardo; Lluch, Ana; Illarramendi, José Juan; Gómez-Pardo, Patricia; Gavilá Gregori, Joaquín; García-Palomo, Andrés; García-Mata, Jesús; Fernández, Yolanda; del Barco, Sonia; de Juan, Ana; Ciruelos, Eva; Chacón, José Ignacio; Calvo, Lourdes; Barnadas, Agustí; Albanell Mestres, Joan (Taylor & Francis, 2019)
    Objective: The aim of this survey conducted by 20 leading Spanish oncologists was to analyze the concurrence between Spanish clinical practice and the recently published definition of the optimal sequence for the systemic ...
  • Contribution of trastuzumab to the prognostic improvement of HER2-positive early breast cancer in Spain: an estimation of life years and disease-free life years gained since its approval
    Ciruelos, Eva; Alba, Emilio; López, Rafael; Lluch, Ana; Martín, Miguel; Arroyo, Isabel; Navarro, Beatriz; Carcedo, David; Colomer, Ramon; Albanell Mestres, Joan (Impact Journals, 2019)
    Introduction: Trastuzumab has become the standard treatment for both HER2-positive early and metastatic breast cancer (HER2+ eBC or mBC) since its approval. The objective of the study is to estimate the benefit of adjuvant ...
  • Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-κB target genes in human breast cancer
    Dalmases Massegú, Alba, 1982-; González González, Irene; Menendez Romero, Silvia; Arpí Llucià, Oriol; Corominas Torres, Josep Maria; Servitja Tormo, Sonia; Tusquets Trias de Bes, Ignacio; Chamizo, Cristina; Rincón, Raúl; Espinosa Blay, Lluís; Bigas Salvans, Anna; Eroles, Pilar; Furriol, Jessica; Lluch, Ana; Rovira Guerín, Ana; Albanell Mestres, Joan; Rojo, Federico (Impact Journals, 2014)
    NF-кB has been linked to doxorubicin resistance in breast cancer patients. NF-кB nuclear translocation and DNA binding in doxorubicin treated-breast cancer cells have been extensively examined; however its functional ...
  • Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis
    Vazquez, Juan Carlos; Antolin, Silvia; Ruiz-Borrego, Manuel; Servitja Tormo, Sonia; Alba, Emilio; Barnadas, Agustí; Lluch, Ana; Martín, Miguel; Rodríguez-Lescure, Álvaro; Solà, Ivan; Bonfill, Xavier; Urrutia, Gerard; Sanchez-Rovira, Pedro (Springer, 2022)
    Background: we aimed to determine the effect of dual anti-HER2 blockade compared to monotherapy on clinically important outcomes. Methods: we carried out a systematic review updated until July 2022. The outcomes included ...
  • Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis.
    Pavlovic, Milica, 1985-; Arnal-Estapé, Anna ; Rojo, Federico; Bellmunt, Anna ; Tarragona, Maria ; Guiu, Marc; Planet, Evarist; Garcia-Albéniz, Xabier; Morales, Mònica; Urosevic, Jelena ; Gawrzak, Sylwia ; Rovira Guerín, Ana; Prat, Aleix; Nonell Mazelón, Lara; Lluch, Ana; Jean-Mairet, Joël ; Coleman, Robert ; Albanell Mestres, Joan; Gomis, Roger R. (Oxford Open , 2015)
    BACKGROUND: There are currently no biomarkers for early breast cancer patient populations at risk of bone metastasis. Identification of mediators of bone metastasis could be of clinical interest. METHODS: A de novo unbiased ...
  • FoxA and LIPG endothelial lipase control the uptake of extracellular lipids for breast cancer growth.
    Slebe Concha, Juan Felipe, 1981-; Rojo, Federico; Vinaixa, Maria; García-Rocha, Mar; Testoni, Giorgia; Guiu, Marc; Planet, Evarist; Samino, Sara; Arenas, Enrique J.; Beltran Marqués, Antoni; Rovira Guerín, Ana; Lluch, Ana; Salvatella, Xavier; Yanes, Oscar; Albanell Mestres, Joan; Guinovart, Joan J. (Joan Josep), 1947-; Gomis, Roger R. (Nature Publishing Group, 2016)
    The mechanisms that allow breast cancer (BCa) cells to metabolically sustain rapid growth are poorly understood. Here we report that BCa cells are dependent on a mechanism to supply precursors for intracellular lipid ...
  • Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines
    Zazo, Sandra; González-Alonso, Paula; Martín-Aparicio, Ester; Chamizo, Cristina; Cristóbal, Ion; Arpí Llucià, Oriol; Rovira Guerín, Ana; Albanell Mestres, Joan; Eroles, Pilar; Lluch, Ana; Madoz-Gúrpide, Juan; Rojo, Federico (e-Century Publishing, 2017)
    Trastuzumab became the therapy of choice for patients with HER2-positive breast cancer in 1998, and it has provided clinical benefit ever since. However, a significant percentage of patients show primary resistance to ...
  • MicroRNA-33b suppresses epithelial-mesenchymal transition repressing the MYC-EZH2 pathway in HER2+ breast carcinoma
    Pattanayak, Birlipta; Garrido Cano, Iris; Adam-Artigues, Anna; Tormo, Eduardo; Pineda, Begoña; Cabello, Paula; Alonso, Elisa; Bermejo, Begoña; Hernando, Cristina; Martínez, María Teresa; Rovira, Ana; Albanell Mestres, Joan; Rojo, Federico; Burgués, Octavio; Cejalvo, Juan M.; Lluch, Ana; Eroles, Pilar (Frontiers, 2020)
    Downregulation of miR-33b has been documented in many types of cancers and is being involved in proliferation, migration, and epithelial-mesenchymal transition (EMT). Furthermore, the enhancer of zeste homolog 2-gene (EZH2) ...
  • miR-146a-5p Promotes angiogenesis and confers Trastuzumab Resistance in HER2+ breast cancer
    Cabello, Paula; Torres-Ruiz, Sandra; Adam-Artigues, Anna; Forés-Martos, Jaume; Martínez, María Teresa; Hernando, Cristina; Zazo, Sandra; Madoz-Gúrpide, Juan; Rovira, Ana; Burgués, Octavio; Rojo, Federico; Albanell Mestres, Joan; Lluch, Ana; Bermejo, Begoña; Cejalvo, Juan Miguel; Eroles, Pilar (MDPI, 2023)
    Trastuzumab treatment has significantly improved the prognosis of HER2-positive breast cancer patients. Despite this, resistance to therapy still remains the main clinical challenge. In order to evaluate the implication ...
  • mTOR inhibition and T-DM1 in HER2-positive breast cancer
    Casadevall Aguilar, David; Hernández Prat, Anna, 1984-; García-Alonso, Sara; Arpí Llucià, Oriol; Menéndez, Silvia; Qin, Mengjuan; Guardia Valenzuela, Cristina, 1990-; Morancho Armisen, Beatriz; Sánchez-Martín, Francisco Javier; Zazo, Sandra; Gavilán, Elena; Sabbaghi Mehrjardi, Mohammad Ali; Eroles, Pilar; Cejalvo, Juan M.; Lluch, Ana; Rojo, Federico; Pandiella, Atanasio; Rovira, Ana; Albanell Mestres, Joan (American Association for Cancer Research (AACR), 2022)
    In patients with trastuzumab-resistant HER2-positive breast cancer, the combination of everolimus (mTORC1 inhibitor) with trastuzumab failed to show a clinically significant benefit. However, the combination of mTOR ...
  • Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer.
    Albanell Mestres, Joan; Svedman, Christer; Gligorov, Joseph; Holt, Simon D.H.; Bertelli, Gianfilippo; Blohmer, Jens-Uwe; Rouzier, Roman; Lluch, Ana; Eiermann, Wolfgang (Elsevier, 2016)
    PURPOSE: The 21-gene Recurrence Score assay (Oncotype DX) provides prognostic/predictive information in oestrogen receptor positive (ER+) early breast cancer, but access/reimbursement has been limited in most European ...
  • PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects.
    Rincón, Raúl; Cristóbal, Ion; Zazo, Sandra; Arpí Llucià, Oriol; Menendez Romero, Silvia; Manso, Rebeca; Lluch, Ana; Eroles, Pilar; Rovira Guerín, Ana; Albanell Mestres, Joan; García-Foncillas, Jesús; Madoz-Gúrpide, Juan; Rojo, Federico (Impact Journals, 2015)
    The protein phosphatase 2A (PP2A) is a key tumor suppressor which has emerged as a novel molecular target in some human cancers. Here, we show that PP2A inhibition is a common event in breast cancer and identified PP2A ...
  • The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors
    Tormo, Eduardo; Ballester, Sandra; Adam-Artigues, Anna; Burgués, Octavio; Alonso, Elisa; Bermejo, Begoña; Menendez Romero, Silvia; Zazo, Sandra; Madoz-Gúrpide, Juan; Rovira Guerín, Ana; Albanell Mestres, Joan; Rojo, Federico; Lluch, Ana; Eroles, Pilar (Nature Research, 2019)
    The mechanisms of chemotherapy resistance in triple negative breast cancer remain unclear, and so, new molecules which might mediate this resistance could optimize treatment response. Here we analyzed the involvement of ...
  • The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene
    Tormo, Eduardo; Adam-Artigues, Anna; Ballester, Sandra; Pineda, Begoña; Zazo, Sandra; González-Alonso, Paula; Albanell Mestres, Joan; Rovira Guerín, Ana; Rojo, Federico; Lluch, Ana; Eroles, Pilar (Nature Publishing Group, 2017)
    A subset of HER2+ breast cancer patients manifest clinical resistance to trastuzumab. Recently, miR-26a and miR-30b have been identified as trastuzumab response regulators, and their target gene CCNE2 seems to play an ...
  • Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial
    Alba, Emilio; Albanell Mestres, Joan; Haba Rodríguez, Juan de la; Barnadas, Agustí; Calvo, Lourdes; Sánchez-Rovira, Pedro; Ramos, Manuel; Rojo, Federico; Burgués, Octavio; Carrasco, Eva María; Caballero, Rosalía; Porras, Ignacio; Tibau, Ariadna; Cámara, Maria del Carmen; Lluch, Ana (Nature Research, 2014)
    Background: The addition of trastuzumab (T) and lapatinib (L) to neoadjuvant chemotherapy increases the pathological complete response (pCR) rate in patients with human epidermal growth factor receptor 2 (HER2)-positive ...

Search DSpace

Browse

My Account

In collaboration with Compliant to Partaking